First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile 

Monisha Sivakumar, Sarah Pawley, Corey Basch, Jimin Park, Justin Kurian, Anthony Reichelderfer, Yue Zou, Kirsten Gallagher, Miles Cowart, Joy Cote, Alexander Grego, Jessica Burtell, Amy Crossan, Michael Hulse, Anjana Agarwal, Arpita Mondal, Chun Chen, Vijay Devannah, Sina Rezazadeh, Quincy Lewis, Patrick Wen, Ken Ray, Raul Leal, Daniel Porreca, Ganfeng Cao, Neha Bhagwat, Shanthi Ganesan, Stefan Ruepp, Min Wang, Joseph Rager, Koichi Ito, Sandy Geeganage, Andrew Combs, Peggy Scherle, Andrew Buesking, Jack Carter